<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: FDA Chief:  Biogenerics will be Similar, Not Interchangeable</title>
	<atom:link href="http://www.patentbaristas.com/archives/2007/03/26/fda-chief-biogenerics-will-be-similar-not-interchangeable/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.patentbaristas.com/archives/2007/03/26/fda-chief-biogenerics-will-be-similar-not-interchangeable/</link>
	<description>Freshly Brewed Bio/Pharma Chat. Served Up Daily.</description>
	<lastBuildDate>Thu, 18 Mar 2010 11:54:35 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Generic Biologics? &#124; worldhealthcareblog.org</title>
		<link>http://www.patentbaristas.com/archives/2007/03/26/fda-chief-biogenerics-will-be-similar-not-interchangeable/comment-page-1/#comment-5501</link>
		<dc:creator>Generic Biologics? &#124; worldhealthcareblog.org</dc:creator>
		<pubDate>Tue, 10 Apr 2007 15:35:03 +0000</pubDate>
		<guid isPermaLink="false">http://www.patentbaristas.com/archives/2007/03/26/fda-chief-biogenerics-will-be-similar-not-interchangeable/#comment-5501</guid>
		<description>[...] That&#8217;s going to be a much higher entry barrier than the standard ANDA process for small-molecule generics, which isn&#8217;t going to help bring down costs. There are a number of tricky regulatory issues as well, and in the end we&#8217;re probably going to have to settle for &#8220;biosimilar&#8221; instead of &#8220;bioequivalent&#8221;. For more details, I can recommend this recent post at PatentBaristas. [...]</description>
		<content:encoded><![CDATA[<p>[...] That&#8217;s going to be a much higher entry barrier than the standard ANDA process for small-molecule generics, which isn&#8217;t going to help bring down costs. There are a number of tricky regulatory issues as well, and in the end we&#8217;re probably going to have to settle for &#8220;biosimilar&#8221; instead of &#8220;bioequivalent&#8221;. For more details, I can recommend this recent post at PatentBaristas. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
